EBMT 2019 | MRD negativity in ALL
Dieter Hoelzer
Dieter Hoelzer, MD, PhD, from the University of Frankfurt, Frankfurt, Germany, explores the importance of MRD negativity in acute lymphoblastic leukemia (ALL). Dr Hoelzer was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.
Related videos
3:33
CAR T-cells for ALL
Ulrich Jäger
1:30
Educating the patient about CAR T-cell therapy
Surbhi Sidana
1:49
CAR T-cell therapy: how caregivers are affected
Surbhi Sidana
1:45
QoL in patients undergoing CAR T-cell therapy versus transplantation
Surbhi Sidana
1:00
CAR-T for ALL: bridging options and choices
Karlo Perica
